Biotech Company Finds DNA-Targeting Drugs with AI in Canada
Analyst Has Confidence in Biotech's Path
Research Report
Isotope Co. Discovers Uranium-Helium Breakthrough Potential
Analyst Shares Thoughts After Microdisplay Co.'s Demo Day
Research Report
Sirens of High Finance
Contributed Opinion
Biotech Boasts Compelling Pipeline
Research Report
California Biotech's Trial Shows Encouraging Results
Research Report
AI-Powered Medical Education Suite Cuts Costs, whilst Enhancing Clinical Skills Training for Future Doctors
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) launched its enhanced medical education suite in Minnesota, showing strong reliability and providing schools with up to 40% cost savings. Read on to find out how AI-simulated patients are reshaping medical education and enhancing clinical skills at scale.Orogen: End of Another Chapter Draws Near
Contributed Opinion
Global Analyst Adrian Day discusses developments at some companies on his list, including Orogen Royalties Inc. (OGN:TSXV; OGNRF:OTCQX) and Franco-Nevada Corp. (FNV:TSX; FNV:NYSE). Q1/25 Financials of Cancer Drug Developer Released
Research Report
Rakovina Therapeutics Inc.'s (RKV:TSX.V) CA$4 million equity offering is nearing completion, noted a Leede Financial Inc. report. Analyst Likes Co. Developing Immuno-oncology Drugs
Research Report
There are multiple reasons to be bullish on this undervalued stock with significant potential upside, noted an H.C. Wainwright & Co. report. New RA Drug Shown to Work, Be Safe
Research Report
"Efficacy at six months represented a 'best case' scenario, in our view," and "safety was very favorable," noted a Wedbush report. Biotech Firm Unveils Diabetes Breakthrough in Canada
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) advanced its Cell Pouch device in Canada with insulin-free outcomes in all trial patients and a CA$6 target price from analysts. Read more to find out how expert advisors, international funding, and a next-gen clinical pipeline could reshape treatment for type 1 diabetes.Phase 2b Trial Data on Treatment for Inflammation Due Soon
Research Report
These results are expected to be favorable based on positive results of a recent interim study, noted a ROTH Capital Partners report. Biotech Co. Reaches MS Clinical Program Milestones
Research Report
These include release of additional Phase 2 trial data and completion of enrollment for two separate Phase 3 studies, noted a D. Boral Capital report. Co.'s New Cancer Drug Shows Promise
Research Report
Preclinical results support this asset's dual mechanism of action in abating cancer drug resistance and reversing cancer-induced immune suppression, noted a D. Boral Capital report. 
Streetwise Key Charts
